Novartis and Generate:Biomedicines forge $1B AI drug discovery deal
Genetic Engineering & Biotechnology News (GEN) - 24-Sep-2024AI and biotech unite for next-gen protein drugs
Join the club for FREE to access the whole archive and other member benefits.
Global medicines company for developing and producing drugs.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 1 billion people globally and we are finding innovative ways to expand access to our latest treatments. About 125 000 people of more than 140 nationalities work at Novartis around the world.
Visit website: https://www.novartis.com/
Details last updated 25-Dec-2019
AI and biotech unite for next-gen protein drugs
Their AlphaFold engine models proteins could lead to faster and more effective treatments
Eli Lilly and Novartis invest in cutting-edge AI to accelerate the search for life-saving treatments
A breakthrough gene therapy restores eyesight in patients with rare eye disease
Company has gathered support from investors to quickly lead therapies to clinic then market
Prescription gene therapy product for treatment of inherited retinal disease
Head of informatics systems at Novartis Institutes for Biomedical Research in Cambridge.